Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants
Status:
Enrolling by invitation
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics
of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple
ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy
elderly (51-75 of age inclusive). The effects of dosing with or without food in healthy
adults will also be studied (optional).